Brief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
09/10/2026 23:40
BRIEF-Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency CytoMed Therapeutics Ltd F98.F:
CYTOMED THERAPEUTICS LIMITED ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY
Source text: ID:nGNX7Ym1vb
Further company coverage: F98.F
Recent news on CytoMed Therapeutics
See all newsBrief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million